Apnimed, Inc.
corporate_fare Company Profile
Apnimed, Inc. (NASDAQ:APMD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for APMD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for APMD spans 10-Q, 8-K.
Recent high-impact activity:
- Apnimed 10-Q: $29.5M Q3 Loss, $351.8M Cash, and a Material Weakness in Controls
- Apnimed Posts $29.5M Q3 Loss; $351.8M Cash Funds Launch Into Q2 2028
- Apnimed Posts $29.5M Q3 Loss as Launch Costs Surge Ahead of Feb 2027 PDUFA
- Apnimed Restates Q2 2026 Financials After SASS Gain Misclassification
- Apnimed Q2: $125.9M Net Income Driven by One-Time Gains; Material Weakness in ICFR Disclosed
Short Interest & Short Volume
4.54 days to coverFINRA reported short interest of 1,586,895 shares in APMD as of the October 30, 2026 settlement, a 12.0% decrease from the prior period — about 4.5 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of APMD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for APMD, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.
IPO Terms Finalized · Pricing Previously Announced
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →